Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

2018109 citationsJournal Articlebronze Open Access

Authors

ClinicalTrials.gov identifier: NCT01783444.

Good health and well-being

Published in: JAMA Oncology

Volume 4, Issue 10, pp. 1367-1367

Field-Weighted Citation Impact: 4.16